# OnCo record nbe-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/nbe-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "nbe-therapeutics" ;
  schema:name "NBE-Therapeutics"@en ;
  schema:description "NBE-Therapeutics, founded in Basel in 2012 and owned by Boehringer Ingelheim since 2020, builds antibody-drug conjugates that pair its own conjugation chemistry with a PNU-derived anthracycline payload, designed to kill tumour cells directly and to trigger a lasting immune response against the tumour. Its candidates are still moving towards the clinic."@en ;
  schema:url <https://onco.cc/companies/nbe-therapeutics/>, <https://nbe-therapeutics.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://nbe-therapeutics.com/>, <https://nbe-therapeutics.com/news-events/news/boehringer-ingelheim-strengthens-antibody-drug-conjugate-portfolio-with-new-nbe-therapeutics-r-d-center-in-basel> ;
  schema:addressCountry "CH" ;
  onco:sections <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/immune-stimulating-adc/> .